Loading
Latest filing published 01 Jun 2026 for 케이엠제약. Read the official filing
No signal scores available.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
All filings by 임영애 on record concern 케이엠제약, in the capacity of chief executive. The record holds 3 filings, for trades running from 2 February 2026 to 19 May 2026.
No open-market sale appears; the market trades are 3 purchases worth €400. The totals do not cover 2 filings with an undisclosed amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.
On 1 June 2026 came the latest disclosure, an open-market purchase in 케이엠제약. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations